Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Roche and Axiogenesis, a German biotechnology company, have entered into an agreement for the development and distribution for Axiogenesis's Cor.At 100% pure cardiomyocytes platform as an integral part of the xCELLigence life cell analysis system. Financial terms of the contract were not disclosed.
Subscribe to our email newsletter
Under the terms of the agreement, Roche Applied Science will market cell-systems, based on the technology of Axiogenesis Cor.At being customized for the xCELLigence platform.
The Roche xCELLigence system is designed for a multitude of applications spanning from short term kinetic analysis, for example, for measuring effects on G-protein coupled receptors, to assays for cell proliferation and cytotoxicity, said Roche. The Cor.At cells from Axiogenesis form an ideal couple to merge the latter qualities to the next level, added Roche.
The cells are not only quality-controlled, storable and available under GMP-conditions but resemble also a physiologically normal phenotype of either neonate or adult heart. This couple therefore enables research studies focusing on long-term life behavior of cardiac cells in vitro.
Manfred Baier, head of Roche Applied Science, said: “After completing our product portfolio in DNA/RNA analysis with 454 and NimbleGen, and the successful launch of the ACEA life cell and label free technology of the xCELLigence System, the Axiogenesis cell portfolio will become an important partner to strengthen and further extend our product portfolio in defined organ specific cell analysis.
“We are convinced that Axiogensis cell and technology portfolio will lead to products for cell-based assays to strengthen our new industrial standard for life science cell-analysis in the future.”